Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

CuraSen begins phase I study of CST-2032 for neurodegenerative disease

Sep. 18, 2020

Toxicity, infectivity separate issues for prion protein

Sep. 18, 2020

PARP1 inhibitor AG-014699 confers neuroprotection in experimental PD

Sep. 17, 2020

INmune receives grant to support phase II testing of XPro-1595 in treatment-resistant depression

Sep. 17, 2020

New rat model of cortical demyelination reveals benefit of anti-CD20 antibody therapy

Sep. 17, 2020

University of California discovers 5-HT2A receptor modulators

Sep. 17, 2020

PZ-1818, a dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor

Sep. 17, 2020

AQP4 and Cx43 expression alteration leads to neuromyelitis optica

Sep. 16, 2020

Phase III trial of ganaxolone in CDKL5 deficiency disorder meets primary endpoint

Sep. 16, 2020

New animal model created to study cerebellar dysfunction in multiple sclerosis

Sep. 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...